PRESS RELEASE published on 02/27/2025 at 08:57, 1 year 6 months ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie ses résultats financiers estimés pour l'année 2024. L'entreprise prolonge son horizon de trésorerie jusqu'à avril 2025 grâce à une gestion rigoureuse et au Crédit d'Impôt Recherche Résultats Financiers Trésorerie GenSight Biologics Crédit D'Impôt Recherche AAC
PRESS RELEASE published on 02/27/2025 at 08:57, 1 year 6 months ago Inside Information / News release on accounts, results GenSight Biologics reports estimated full-year 2024 consolidated financial results. Cash runway extended to early April 2025. Resumption of Compassionate Access Program expected in April 2025 Financial Results 2024 GenSight Biologics Cash Runway Compassionate Access Program
BRIEF published on 02/12/2025 at 07:35, 1 year 6 months ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
BRIEF published on 02/12/2025 at 07:35, 1 year 6 months ago GenSight Biologics annonce des résultats positifs sur cinq ans pour la thérapie génique LUMEVOQ® Thérapie Génique LUMEVOQ® Acuité Visuelle Profil De Sécurité Étude REFLECT
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 6 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats à 5 ans de la thérapie génique LUMEVOQ® pour la NOHL, confirmant l'efficacité durable et le profil de sécurité favorable Sécurité Efficacité Thérapie Génique GenSight Biologics LUMEVOQ
BRIEF published on 01/23/2025 at 18:50, 1 year 7 months ago GenSight Biologics : Bilan Financier et Perspectives GenSight Biologics LUMEVOQ® Augmentations De Capital Accès Compassionnel Trésorerie 2024
BRIEF published on 01/23/2025 at 18:50, 1 year 7 months ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 7 months ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation financière 2024 et donne des mises à jour sur ses activités, y compris le financement et la progression réglementaire de LUMEVOQ. La trésorerie s'élève à 2,5M€ à fin 2024 Financement Trésorerie Situation Financière GenSight Biologics LUMEVOQ
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 7 months ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
Published on 09/10/2026 at 22:25, 4 hours 49 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 11 hours 54 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 12 hours 14 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 12 hours 37 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 3 hours 8 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 3 hours 13 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 4 hours 34 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 5 hours 3 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 5 hours 6 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 7 hours 44 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 7 hours 44 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 9 hours 4 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 9 hours 29 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 9 hours 31 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
